Tumor necrosis factor-alpha, biologic agents and cardiovascular risk

Area of Science:

• Cardiovascular Medicine
• Rheumatology
• Immunology

Background:

• Rheumatoid arthritis (RA) is associated with an increased risk of premature cardiovascular disease (CVD).
• RA-specific factors, including dyslipidemia and pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-alpha), contribute to this elevated CVD risk.
• TNF-alpha, a key inflammatory mediator, plays a role in cardiac stress, atherosclerosis, and adverse cardiac manifestations.

Purpose of the Study:

• To explore the role of TNF-alpha in cardiovascular complications in RA patients.
• To evaluate the potential of anti-TNF-alpha biologic agents in mitigating cardiovascular risk in RA.
• To assess the controversial effects of TNF-alpha blockers on incident congestive heart failure (CHF) in RA.

Main Methods:

• Review of existing literature on TNF-alpha, RA, and cardiovascular disease.
• Analysis of clinical trial data regarding anti-TNF-alpha therapies in RA and CVD.
• Examination of the impact of TNF-alpha inhibition on atherosclerosis and heart failure development.

Main Results:

• Anti-TNF-alpha biologic agents have demonstrated significant clinical benefits in inflammatory diseases like RA.
• While promising for RA, recent studies antagonizing TNF-alpha in CVD have yielded disappointing results, with varied explanations.
• The efficacy of TNF-alpha blockers in preventing incident congestive heart failure (CHF) in RA patients remains controversial.

Conclusions:

• Anti-TNF-alpha agents should not be used for treating New York Heart Association (NYHA) class III or IV heart failure due to a lack of evidence for benefit.
• Further research is needed to clarify the precise role of TNF-alpha in CVD pathogenesis and the selective use of its inhibitors in RA patients with cardiac conditions.